Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Diagnostics » Molecular Diagnostics » Study Validates Oncotype DX AR-V7 Chemo Prediction

Study Validates Oncotype DX AR-V7 Chemo Prediction

Jun 28, 2018
|
staff reporter

NEW YORK (GenomeWeb) – A newly published  multi-institutional cohort study has validated Epic Sciences' circulating tumor cell-based AR-V7 test, now marketed by Genomic Health as Oncotype DX AR-V7 Nucleus Detect.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Finds a Whole Bunch

A new blood test might be able to detect the presence of some 50 cancers, according to New Scientist.

Away From the Field

Undark looks into how coronavirus-related shutdowns are affecting field researchers.

PNAS Studies Look at Bacterial Detection Probes, Cholera Culprit Evolution in Environment, More

In PNAS this week: strategies to design DNA oligonucleotide probes for bacteria, Vibrio cholerae evolution in Haiti, and more.

In a Different Lab

NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.

May
06
Featured Webinar

The Role of Single-Cell Functional Biomarkers in Next-Generation Cancer Therapies

Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.

What's Popular?

In Molecular Diagnostics

  1. Qiagen Receives FDA Emergency Use Authorization for SARS-CoV-2 Respiratory Panel

  2. Abbott POC Coronavirus Test Snares FDA Emergency Use Authorization

  3. Bio-Rad Laboratories ddPCR Shows Accuracy Benefits in COVID-19 Detection Studies

  4. Cue Health Awarded $13M BARDA Contract for POC Coronavirus Test

  5. Exact Sciences, Promega Aiding in COVID-19 Testing in Wisconsin

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.